Stonegate Investment Group’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$465K Buy
4,190
+118
+3% +$13.4K 0.01% 256
2025
Q2
$451K Sell
4,072
-256
-6% -$27.2K 0.01% 253
2025
Q1
$485K Sell
4,328
-1,819
-30% -$188K 0.01% 222
2024
Q4
$568K Sell
6,147
-641
-9% -$57.7K 0.02% 202
2024
Q3
$569K Sell
6,788
-244
-3% -$18.6K 0.02% 213
2024
Q2
$482K Buy
7,032
+29
+0.4% +$1.94K 0.01% 230
2024
Q1
$513K Sell
7,003
-294
-4% -$22.6K 0.02% 216
2023
Q4
$591K Buy
7,297
+460
+7% +$35.8K 0.02% 193
2023
Q3
$512K Buy
6,837
+2,923
+75% +$225K 0.02% 197
2023
Q2
$302K Sell
3,914
-1,500
-28% -$120K 0.01% 251
2023
Q1
$449K Sell
5,414
-75
-1% -$6.21K 0.02% 217
2022
Q4
$471K Sell
5,489
-135
-2% -$10.7K 0.02% 208
2022
Q3
$347K Buy
5,624
+726
+15% +$45.8K 0.02% 212
2022
Q2
$303K Buy
+4,898
New +$303K 0.01% 231
2022
Q1
Sell
-3,132
Closed -$227K 305
2021
Q4
$227K Buy
+3,132
New +$216K 0.01% 235

Other funds holding GILD

Stonegate Investment Group's GILD Position: Q3 2025 in Review

Stonegate Investment Group increased its Gilead Sciences (GILD) stake by 2.9% in Q3 2025, buying an estimated $13.4K and bringing the position to 4,190 shares worth $465K. The position accounts for 0.01% of the portfolio, ranked #256.

Stonegate Investment Group first reported a position in GILD in Q4 2021 and has held it in 15 quarters since. The position peaked at $591K in Q4 2023. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

  • Stonegate Investment Group held 4,190 shares of Gilead Sciences worth $465K as of Q3 2025.
  • Stonegate Investment Group bought 118 Gilead Sciences shares in Q3 2025, an estimated $13.4K.
  • Gilead Sciences made up 0.01% of Stonegate Investment Group's portfolio in Q3 2025, its #256 holding.
  • Stonegate Investment Group first reported a position in Gilead Sciences in Q4 2021 and has held it in 15 quarters since.
  • Stonegate Investment Group's Gilead Sciences position peaked at $591K in Q4 2023.
  • 2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on Stonegate Investment Group's 13F filing for Q3 2025, filed 3 Nov 2025.